Report overview
HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
This report aims to provide a comprehensive presentation of the global market for Hepatocellular Carcinoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocellular Carcinoma Drugs. This report contains market size and forecasts of Hepatocellular Carcinoma Drugs in global, including the following market information:
Global Hepatocellular Carcinoma Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Hepatocellular Carcinoma Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.
We surveyed the Hepatocellular Carcinoma Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hepatocellular Carcinoma Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Hepatocellular Carcinoma Drugs Market Segment Percentages, by Type, 2022 (%)
Brachytherapy
Chemotherapy
Local Ablation Therapy
Global Hepatocellular Carcinoma Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Hepatocellular Carcinoma Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Cancer Rehabilitation Centers
Global Hepatocellular Carcinoma Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Hepatocellular Carcinoma Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hepatocellular Carcinoma Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hepatocellular Carcinoma Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Eli Lilly
Johnson and Johnson
Pfizer
Bristol-Myers Squibb
Celgene
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck
Novartis
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hepatocellular Carcinoma Drugs, market overview.
Chapter 2: Global Hepatocellular Carcinoma Drugs market size in revenue.
Chapter 3: Detailed analysis of Hepatocellular Carcinoma Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hepatocellular Carcinoma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
